87840 20231023123341.0 sideral 116225 ART-2019-116225 eng Frutos Pérez-Surio, Alberto Universidad de Zaragoza (orcid)0000-0001-9962-3387 Drug-drug interactions between tyrosine kinase inhibitors and concomitant medications: drug safety in chronic myeloid leukemia treatment. 2019 Access copy available to the general public Unrestricted Background: Clinical Pharmacist should be aware of hematologic toxicities from tyrosine kinase inhibitors (TKI) used to treat chronic myelogenous leukemia (CML). Drug-drug interactions (DDI) may be problematic. Objective: To analyze DDI between TKI and the concomitant medication. Setting: Retrospective observational study carried in a tertiary hospital of Spain. Method: A bibliographic search was made on the UpToDate®, Lexicomp® and Micromedex® software platforms to search for evidence on DDI between TKI and the concomitant medication. Main outcome measure: Number of interactions with respect to sex,to number of concomitant drugs, and to TKI used. Results: A total of 28 patients were analyzed. 78.6% of patients had medication associated with the TKI. There was a total of 50 significant DDI, out of a total of 128 drugs, so the risk of having interaction in the study population was 39.1%. Regarding the management of the interactions by the hematologist and the acceptance of the pharmaceutical intervention: 10 patients experienced 14 high-level interactions. Of these the doctor knew 50% and had performed intervention in all cases: modify the treatment in 28.6%, consulted with service responsible for treatment in 42.8% and spaced the intake of drugs in 28.6%. It is important to periodically review concomitant medication and to have a strategy to manage interactions. The role of the clinical pharmacist is essential in communication with the patient, assessment of treatments, detecting potential interactions and disseminating information among the multidisciplinary team. Conclusion: All patients who are prescribed oral antineoplastic drugs are provided patient education materials about TKI, which include possible interactions. Any changes in the patient’s medications prompt a review for DDI. info:eu-repo/semantics/openAccess by-nc-nd http://creativecommons.org/licenses/by-nc-nd/3.0/es/ 0.101 2019 Pharmacology 2019 Q4 Pharmaceutical Science 2019 Q4 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Lozano Ortiz, Roberto Martinez Crespo, Alejandro 1008 615 Universidad de Zaragoza Dpto. Microb.Med.Pr.,Sal.Públ. Área Medic.Prevent.Salud Públ. 31, 4 (2019), 192-200 Pharmakeftiki 1105-4999 257546 http://zaguan.unizar.es/record/87840/files/texto_completo.pdf Versión publicada 415848 http://zaguan.unizar.es/record/87840/files/texto_completo.jpg?subformat=icon icon Versión publicada https://www.hsmc.gr/en/pharmakeftiki-journal/ Texto completo de la revista oai:zaguan.unizar.es:87840 articulos driver 2023-10-23-12:20:46 ARTICLE